TREATMENT FAILURE Twelve (22%) patients in the survey stopped treatment before the 6-month analysis compared to 3% reported in the trials.[[1], [3]] Nine of these patients stopped treatment due to adverse side effects. This included the validated tool for patient-reported outcome measures, the Angioedema Control Test (AECT).[6] BASELINE PROPHYLAXIS Most patients (32, 59.3%) were receiving prophylaxis prior to starting berotralstat. To the Editor, Berotralstat is an oral plasma kallikrein inhibitor, used for routine prevention of attacks of hereditary angioedema (HAE) Type 1 and Type 2. [Extracted from the article]